Biologically-targeted detection of primary and micro-metastatic ovarian cancer

Theranostics

Volumn 3, Issue 6, 2013, Pages 420-427

  Liu, Tracy W ^a   Stewart, Jocelyn M ^a   MacDonald, Thomas D ^b   Chen, Juan ^a   Clarke, Blaise ^c   Shi, Jiyun ^a,d   Wilson, Brian C ^a   Neel, Benjamin G ^a   Zheng, Gang ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PEKING UNIVERSITY   (China)

Author keywords

Fluorescence imaging; Folate receptor; Multimodal; Ovarian cancer; PET

Indexed keywords

PORPHYRIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL TRANSPORT; EX VIVO STUDY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MICROMETASTASIS; MICROSCOPY; MOLECULAR PROBE; NONHUMAN; OMENTUM; OVARY CANCER; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROTEIN TARGETING; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84883173560     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.6413     Document Type: Article

References (26)

1. Committee CCSsS. Statistics for ovarian cancer. Canadian Cancer Encycolpedia from Canadian Cancer Society. 2010.
2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012; 460: 237-49. doi:10.1007/s00428-012-1203-5.
3. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009; 361: 170-7. doi:361/2/170 [pii] 10.1056/NEJMcp0901926.
4. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011; 71: 1397-412. doi:10.2165/11591720-000000000-00000.
5. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic oncology. 2008; 108: 619-26. doi:10.1016/j.ygyno.2007.11.020.
6. Siegel BA, Dehdashti F, Mutch DG, Podoloff DA, Wendt R, Sutton GP, et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2003; 44: 700-7.
7. White RLC AJ, Armstrong DK, Glenn D, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study [abstract no 5001]. J Clin Oncol. 2010; 28.
8. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nature medicine. 2011; 17: 1315-9. doi:10.1038/nm.2472.
9. Symanowski JT, Maurer AH, Naumann RW, Shah NP, Morgenstern D, Messmann RA. Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer. ASCO Meeting Abstracts. 2010; 28: 5034.
10. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nuclear medicine communications. 2008; 29: 193-207. doi:10.1097/MNM.0b013e3282f3a515.
11. Stefflova K, Li H, Chen J, Zheng G. Peptide-based pharmacomodulation of a cancer-targeted optical imaging and photodynamic therapy agent. Bioconjug Chem. 2007; 18: 379-88. doi:10.1021/bc0602578.
12. Shi J, Liu TW, Chen J, Green D, Jaffray D, Wilson BC, et al. Transforming a targeted porphyrin theranostic agent into a PET imaging probe for cancer. Theranostics. 2011; 1: 363-70.
13. Liu TW, Chen J, Burgess L, Cao W, Shi J, Wilson BC, et al. Multimodal bacteriochlorophyll theranostic agent. Theranostics. 2011; 1: 354-62.
14. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A. 2011; 108: 6468-73. doi:10.1073/pnas.1005529108.
15. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004; 10: 1032-42. doi:10.1016/j.ymthe.2004.08.013.
16. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nature reviews Clinical oncology. 2010; 7: 381-93. doi:10.1038/nrclinonc.2010.47.
17. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR American journal of roentgenology. 2010; 194: W464-70. doi:10.2214/AJR.09.3843.
18. Musto A, Rampin L, Nanni C, Marzola MC, Fanti S, Rubello D. Present and future of PET and PET/CT in gynaecologic malignancies. European journal of radiology. 2011; 78: 12-20. doi:10.1016/j.ejrad.2009.12.035.
19. Crane LM, van Oosten M, Pleijhuis RG, Motekallemi A, Dowdy SC, Cliby WA, et al. Intraoperative imaging in ovarian cancer: fact or fiction? Molecular imaging. 2011; 10: 248-57. doi:10.2310/7290.2011.00004.
20. Sheth RA, Upadhyay R, Stangenberg L, Sheth R, Weissleder R, Mahmood U. Improved detection of ovarian cancer metastases by intraoperative quantitative fluorescence protease imaging in a pre-clinical model. Gynecologic oncology. 2009; 112: 616-22. doi:10.1016/j.ygyno.2008.11.018.
21. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews Cancer. 2009; 9: 415-28. doi:10.1038/nrc2644.
22. Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecologic oncology. 2012; 126: 224-8. doi:10.1016/j.ygyno.2012.05.001.
23. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376: 1155-63. doi:10.1016/S0140-6736(10)61268-8.
24. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. European journal of radiology. 2009; 71: 164-74. doi:10.1016/j.ejrad.2008.02.019.
25. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. The New England journal of medicine. 1983; 309: 883-7. doi:10.1056/NEJM198310133091503.
26. Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12: 2517-25. doi:10.1158/1078-0432.CCR-05-1625.